Nifekalant Hydrochloride (BioDeep_00000705559)

   


代谢物信息卡片


Nifekalant Hydrochloride

化学式: C19H28ClN5O5 (441.17788680000007)
中文名称: 盐酸奈非卡那特(MS-551), 尼非卡兰
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CN1C(=CC(=O)N(C1=O)C)NCCN(CCCC2=CC=C(C=C2)[N+](=O)[O-])CCO.Cl
InChI: 1H

描述信息

D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

同义名列表

1 个代谢物同义名

Nifekalant Hydrochloride



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Jiashan Zhang, Ying Zan, Hua Huo, Yanfang Liu, Yunbiao Tang, Yaling Han. Population pharmacokinetic/pharmacodynamic modelling of nifekalant in healthy Chinese volunteers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2020 Aug; 151(?):105385. doi: 10.1016/j.ejps.2020.105385. [PMID: 32454129]
  • Mengmeng Zhang, Guobing Shi, Yin Sui, Ye An, Ming Yan, Yunbiao Tang. The application of an LC-MS/MS method in a pharmacokinetic study for the determination of the concentration of nifekalant in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013 Nov; 938(?):105-10. doi: 10.1016/j.jchromb.2013.09.003. [PMID: 24076524]
  • Yi Zhou, Xiu-Mei Liu, Ling Wang, Xue-Hua Jiang. An HPLC method for the determination of nifekalant hydrochloride in canine plasma and its application to a pharmacokinetic study. Journal of chromatographic science. 2013 Oct; 51(9):867-71. doi: 10.1093/chromsci/bms182. [PMID: 23169932]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • Hiroshi Furukawa, Hitoshi Aono, Masanobu Samukawa, Kohichiro Iwasaki, Akihiko Ohkado. [Clinical experience with intravenous administration of nifekalant hydrochloride for ventricular tachycardia in a hemodialysis patient after open heart surgery]. Kyobu geka. The Japanese journal of thoracic surgery. 2010 Oct; 63(11):988-91. doi: NULL. [PMID: 20954355]
  • Jing Wang, Wei Hua, Jun Zhu, Yan-Min Yang, Fang-Zheng Wang, Jie-Lin Pu, Ke-Ping Chen, Shu Zhang. Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation. Chinese medical journal. 2010 Aug; 123(15):2028-33. doi: NULL. [PMID: 20819537]
  • Koichiro Yoshioka, Mari Amino, Seiji Morita, Yoshihide Nakagawa, Kazutane Usui, Atsuhiko Sugimoto, Atsushi Matsuzaki, Yoshiaki Deguchi, Isotoshi Yamamoto, Sadaki Inokuchi, Yuji Ikari, Itsuo Kodama, Teruhisa Tanabe. Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)? : comparative study of out-of-hospital CPA with acidosis and in-hospital CPA without acidosis. Circulation journal : official journal of the Japanese Circulation Society. 2006 Jan; 70(1):21-7. doi: 10.1253/circj.70.21. [PMID: 16377919]
  • Masanori Hirose, Masahito Miura, Yuji Wakayama, Hideaki Endo, Yoshinao Sugai, Bruno D M Y Stuyvers, Yutaka Kagaya, Jun Watanabe, Henk E D J ter Keurs, Kunio Shirato. Effect of nifekalant, a class III anti-arrhythmic agent, on Ca2+ waves in rat intact trabeculae. Circulation journal : official journal of the Japanese Circulation Society. 2005 Jun; 69(6):739-45. doi: 10.1253/circj.69.739. [PMID: 15914955]
  • Masaki Igarashi, Tadashi Fujino, Miwako Toyoda, Keishi Sugino, Kenichirou Sasao, Shuichi Sasamoto, Takayuki Otsuka, Kenzaburo Kobayashi, Yoshifumi Okano, Katsunori Yosiwara, Nobuya Koyama. Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation. Pacing and clinical electrophysiology : PACE. 2005 Jan; 28 Suppl 1(?):S155-7. doi: 10.1111/j.1540-8159.2005.00043.x. [PMID: 15683486]
  • Yoshioki Satoh, Atsushi Sugiyama, Akira Takahara, Katsuyoshi Chiba, Keitaro Hashimoto. Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. Journal of cardiovascular pharmacology. 2004 May; 43(5):715-23. doi: 10.1097/00005344-200405000-00015. [PMID: 15071360]
  • Masafumi Myoishi, Satoshi Yasuda, Shunichi Miyazaki, Kazuyuki Ueno, Isao Morii, Kazuhiro Satomi, Yoritaka Otsuka, Atsushi Kawamura, Takashi Kurita, Shiro Kamakura, Hiroshi Nonogi. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis. Circulation journal : official journal of the Japanese Circulation Society. 2003 Oct; 67(10):898-900. doi: 10.1253/circj.67.898. [PMID: 14578629]